DURECT Corp (DRRX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:DURECT Corp (DRRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014199
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company’s product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect’s major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
DURECT Corp, Medical Devices Deals, 2011 to YTD 2017 9
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
DURECT Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Durect Enters into Licensing Agreement with Santen Pharma 11
Licensing Agreements 12
Sandoz Enters into Licensing Agreement with DURECT 12
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 13
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 15
Otonomy Enters into Licensing Agreement with Durect 16
DURECT Amends Licensing Agreement With Nycomed 17
Equity Offering 19
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 22
Durect Completes Public Offering Of Shares For US$11.5 Million 23
Durect Completes Public Offering Of Shares For US$13 Million 24
Asset Transactions 25
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp – Key Competitors 26
DURECT Corp – Key Employees 27
DURECT Corp – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 29
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 31
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 33
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 35
Oct 31, 2016: DURECT Announces Third Quarter 2016 Financial Results and Update of Programs 37
Aug 01, 2016: DURECT Announces Second Quarter 2016 Financial Results and Update of Programs 39
May 05, 2016: DURECT Announces First Quarter 2016 Financial Results and Update of Programs 41
Feb 29, 2016: DURECT Announces Fourth Quarter 2015 Financial Results and Update of Programs 43
Corporate Communications 45
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 45
Product News 46
04/07/2016: DURECT Announces POSIMIR Program Update 46
Clinical Trials 47
Jun 22, 2017: DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
DURECT Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Deals By Therapy Area, 2011 to YTD 2017 8
DURECT Corp, Medical Devices Deals, 2011 to YTD 2017 9
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Durect Enters into Licensing Agreement with Santen Pharma 11
Sandoz Enters into Licensing Agreement with DURECT 12
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 13
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 15
Otonomy Enters into Licensing Agreement with Durect 16
DURECT Amends Licensing Agreement With Nycomed 17
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 22
Durect Completes Public Offering Of Shares For US$11.5 Million 23
Durect Completes Public Offering Of Shares For US$13 Million 24
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp, Key Competitors 26
DURECT Corp, Key Employees 27

★海外企業調査レポート[DURECT Corp (DRRX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boparan Holdings Ltd:企業の戦略的SWOT分析
    Boparan Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Development Bank of Southern Africa:企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • SNGN Romgaz SA (SNG):石油・ガス:M&Aディール及び事業提携情報
    Summary SNGN Romgaz SA (Romgaz), formerly Societatea Nationala de Gaze Naturale Romgaz SA, is an oil and gas company which explores, produces and supplies natural gas. The company's activities include exploration of petroleum onshore and offshore, natural gas production, electric power production, t …
  • Patterson-UTI Energy Inc (PTEN):企業の財務・戦略的SWOT分析
    Patterson-UTI Energy Inc (PTEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • West Corporation:企業の戦略的SWOT分析
    West Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Matthews International Corp (MATW):企業の財務・戦略的SWOT分析
    Matthews International Corp (MATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • LyondellBasell Industries NV (LYB):石油・ガス:M&Aディール及び事業提携情報
    Summary LyondellBasell Industries NV (LyondellBasell) is a chemical company. It produces and sells petrochemicals, plastics and basic chemicals. The company also refines crude oil to convert into refined products such as gasoline, diesel and jet fuel. Its major chemical products include polyolefins …
  • scPharmaceuticals Inc (SCPH):製薬・医療:M&Aディール及び事業提携情報
    Summary ScPharmaceuticals Inc (scPharmaceuticals) is a clinical-stage pharmaceutical company. The company’s pipeline products include subcutaneous formulations of furosemide, ceftriaxone and carbapenem. Its furosemide formulation is a loop diuretic widely used in prescription pharmaceuticals for the …
  • Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhangzhou Pientzehuang Pharmaceutical Co Ltd (Pientzehuang), a subsidiary of Zhangzhou Jiulongjiang Construction Co Ltd, is a pharmaceutical company that manufactures and markets traditional Chinese medicines. The company develops medicines and health products, cosmetics, daily chemicals, me …
  • Berkshire Hathaway Energy Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Berkshire Hathaway Energy Company (BHE) a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources su …
  • Impol Seval A.D. Sevojno
    Impol Seval A.D. Sevojno - Strategy, SWOT and Corporate Finance Report Summary Impol Seval A.D. Sevojno - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tiziana Life Sciences Plc (TILS):製薬・医療:M&Aディール及び事業提携情報
    Summary Tiziana Life Sciences Plc (Tiziana), formerly Alexander David Investments Plc, is a clinical stage biotechnology company that discovers and develops drugs to treat diseases in oncology and immunology. The company’s lead product candidate, TZLS-201, intended for the treatment of thymic carcin …
  • Groupe SMCP S.A.S.:企業の戦略的SWOT分析
    Groupe SMCP S.A.S. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Wellcome Trust Sanger Institute-医療機器分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Ingram Micro Inc:企業の戦略的SWOT分析
    Ingram Micro Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Getinge AB (GETI B):企業の財務・戦略的SWOT分析
    Getinge AB (GETI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • Neurones SA (FR0004050250NRO):企業の財務・戦略的SWOT分析
    Neurones SA (FR0004050250NRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Quilvest Wealth Management:企業の戦略・SWOT・財務分析
    Quilvest Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Quilvest Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆